Calan: Advanced Calcium Channel Blocker for Hypertension & Angina Control
Calan
| Product dosage: 120mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | 0.90 $ | 53.82 $ (0%) | 🛒 Add to cart |
| 90 | 0.74 $ | 80.73 $ 66.69 $ (17%) | 🛒 Add to cart |
| 120 | 0.65 $ | 107.64 $ 78.39 $ (27%) | 🛒 Add to cart |
| 180 | 0.57 $ | 161.46 $ 102.96 $ (36%) | 🛒 Add to cart |
| 270 | 0.52 $ | 242.19 $ 141.57 $ (42%) | 🛒 Add to cart |
| 360 | 0.50 $
Best per pill | 322.92 $ 179.01 $ (45%) | 🛒 Add to cart |
| Product dosage: 240mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | 1.09 $ | 65.52 $ (0%) | 🛒 Add to cart |
| 90 | 0.96 $ | 98.28 $ 86.58 $ (12%) | 🛒 Add to cart |
| 120 | 0.91 $ | 131.04 $ 108.81 $ (17%) | 🛒 Add to cart |
| 180 | 0.84 $ | 196.56 $ 152.10 $ (23%) | 🛒 Add to cart |
| 270 | 0.81 $ | 294.84 $ 218.79 $ (26%) | 🛒 Add to cart |
| 360 | 0.79 $
Best per pill | 393.12 $ 283.14 $ (28%) | 🛒 Add to cart |
Calan (verapamil hydrochloride) is a trusted calcium channel blocker prescribed for managing hypertension, chronic stable angina, and certain arrhythmias. By inhibiting calcium influx into vascular smooth muscle and cardiac cells, Calan effectively reduces peripheral vascular resistance and myocardial oxygen demand. This medication offers a well-established option for cardiovascular patients requiring consistent blood pressure control and angina prophylaxis, supported by decades of clinical use and research.
Features
- Active ingredient: Verapamil hydrochloride
- Available in immediate-release and extended-release formulations
- Standard strengths: 40 mg, 80 mg, 120 mg, 180 mg, 240 mg tablets
- Some formulations designed for once-daily dosing
- Coated tablets for easier swallowing
- Manufactured under strict pharmaceutical quality standards
Benefits
- Effectively lowers blood pressure, reducing long-term cardiovascular risk
- Decreases frequency and severity of angina episodes
- Helps control certain types of cardiac arrhythmias
- May be used as monotherapy or in combination with other antihypertensives
- Extended-release formulations support consistent 24-hour coverage
- Well-established safety profile with extensive clinical documentation
Common use
Calan is primarily indicated for the management of essential hypertension, either as monotherapy or in combination with other antihypertensive agents. It is also approved for the treatment of chronic stable angina pectoris and for the control of ventricular rate in patients with atrial fibrillation or flutter. Some clinicians may use Calan off-label for migraine prophylaxis or in certain cases of hypertrophic cardiomyopathy, though these uses require careful medical supervision.
Dosage and direction
Dosage must be individualized based on patient response and tolerability. For hypertension: Initial dose typically ranges from 80-120 mg three times daily (immediate-release) or 180-240 mg once daily (extended-release). Maximum daily dose should not exceed 480 mg. For angina: Initial dose of 80-120 mg three times daily, titrated upward at weekly intervals. For arrhythmias: Dosage varies significantly based on specific condition and patient status. Always take with food to minimize gastrointestinal upset. Do not crush or chew extended-release tablets. Regular blood pressure monitoring is essential during dosage adjustments.
Precautions
Patients should undergo thorough cardiovascular assessment before initiation. Regular monitoring of blood pressure, heart rate, and ECG is recommended, especially during dosage titration. Use with caution in patients with impaired hepatic or renal function, requiring dosage adjustments. May mask hypoglycemia symptoms in diabetic patients. Gradual withdrawal is recommended to avoid rebound hypertension or angina. Patients should avoid sudden position changes to minimize orthostatic hypotension risk.
Contraindications
Calan is contraindicated in patients with severe left ventricular dysfunction, hypotension (systolic pressure <90 mmHg), sick sinus syndrome or second- or third-degree AV block (unless a functioning ventricular pacemaker is present), atrial flutter or fibrillation with an accessory bypass tract, and known hypersensitivity to verapamil. Concurrent use with ivabradine is contraindicated. Should not be administered to patients with cardiogenic shock.
Possible side effect
Common side effects include constipation (approximately 7%), dizziness (3%), nausea (2%), hypotension (2%), and headache (2%). Less frequently, patients may experience edema, fatigue, bradycardia, flushing, or elevated liver enzymes. Serious but rare adverse effects include heart failure exacerbation, severe bradycardia, AV block, hepatotoxicity, or gingival hyperplasia. Most side effects are dose-dependent and often diminish with continued therapy.
Drug interaction
Calan has numerous significant drug interactions. Potentiates effects of other antihypertensives. Concurrent use with beta-blockers may lead to excessive bradycardia or heart block. Increases digoxin levels by 50-75%. May increase levels of simvastatin, lovastatin, and cyclosporine. CYP3A4 inhibitors (ketoconazole, erythromycin) increase verapamil concentrations. Rifampin decreases verapamil levels. Use with dantrolene may cause hyperkalemia. Disopyramide should not be administered within 48 hours before or 24 hours after verapamil.
Missed dose
If a dose is missed, take it as soon as remembered unless it is nearly time for the next scheduled dose. Do not double the dose to make up for a missed one. For once-daily formulations, if missed and remembered within 12 hours, take immediately; if beyond 12 hours, skip and resume regular schedule. Maintaining consistent dosing is crucial for stable blood pressure control. Patients should establish routine medication habits and consider using pill organizers or reminder systems.
Overdose
Symptoms of overdose include severe hypotension, bradycardia, heart failure, and conduction disturbances. Management involves cardiovascular support and monitoring. Calcium gluconate (10%) 10-20 mL IV may reverse hemodynamic effects. For significant bradycardia, atropine, isoproterenol, or cardiac pacing may be necessary. Dopamine or norepinephrine can address hypotension. Hemodialysis is not effective due to high protein binding. All suspected overdoses require immediate medical attention and hospitalization.
Storage
Store at controlled room temperature (20-25°C or 68-77°F) in original container. Protect from light and moisture. Keep tightly closed and away from excessive heat. Do not store in bathroom medicine cabinet due to humidity fluctuations. Keep out of reach of children and pets. Properly discard expired medication or unused portions through medication take-back programs. Do not flush medications down toilet or drain unless specifically instructed.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Calan is a prescription medication that should only be used under the supervision of a qualified healthcare professional. Individual patient needs may vary, and this information cannot replace personalized medical guidance. Always consult with your physician before starting, stopping, or changing any medication regimen. Report any adverse effects to your healthcare provider promptly.
Reviews
Clinical studies consistently demonstrate Calan’s efficacy in blood pressure reduction and angina management. In the CONVINCE trial, verapamil-based therapy showed comparable cardiovascular protection to conventional treatment. Many clinicians appreciate its dual benefits for hypertension and angina. Patients often report improved quality of life with adequate symptom control. Some note constipation as a manageable side effect with proper dietary adjustments. Overall, Calan remains a valuable option in cardiovascular therapeutics with extensive real-world experience supporting its use.